arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Axsome Therapeutics, Inc.

AXSM
$129.90 ▼ -7.05 (-5.15%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
13 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Axsome Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.5B
Dividend Yield —
Revenue Growth 65.5% ↗
Op. Margin -26.1% ↗
ROIC -80.7% ↗
FCF / Share $-1.89 ↗
Trailing P/E —
Price / Book 74.9x
FCF Yield —
Debt / Equity 1.33
info Valuation on last close. End-of-day price, Nov 5, 2026.

13-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$638.50M
↑ +65.5% —
Net Income Profit after all expenses
$-183.17M
↑ +36.2% —
Operating Margin Operating profit as % of sales
-26.1%
↑ +64.1% 9th
FCF / Share Free cash flow per share
$-1.89
↑ +29.7% —
Long-Term Debt Long-term obligations
$117.75M
↓ -34.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
9
Returns ↓
2
Financial Health →
25
Cash Quality ↓
41

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 13 years · 49 quarters